Project Details
Project Description
To appraise the clinical and cost-effectiveness and budget impact of sacituzumab govitecan for patients with unresectable locally advanced or metastatic HR positive, HER2 negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
| Status | Finished |
|---|---|
| Effective start/end date | 1/06/24 → 31/12/24 |